XTL Biopharmaceuticals
XTLB
2 hedge funds and large institutions have $316K invested in XTL Biopharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
8% more capital invested
Capital invested by funds: $293K → $316K (+$22.4K)
0.03% less ownership
Funds ownership: 4.44% → 4.42% (-0.03%)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.56K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$363 |
XTLB Hedge Fund Activity: Q1 2023 in Review
2 of the 6,285 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2023, worth a combined $316K — up 7.6% from $293K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Morgan Stanley, cutting an estimated $1.56K.
- 2 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2023, down from 3 in Q4 2022.
- Funds reported $316K of XTL Biopharmaceuticals stock for Q1 2023, up 7.6% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q1 2023 and 1 closed out, a net change of -1 holder.
- The largest XTL Biopharmaceuticals seller in Q1 2023 was Morgan Stanley, an estimated $1.56K sold.
Based on aggregated 13F filings for Q1 2023.